Kozyreff Alexandra, Bughin Alice, Lefebvre Chantal, Pothen Lucie, Yildiz Halil
Cliniques universitaires Saint-Luc, Catholic University of Louvain, Brussels, Belgium.
Uveitis Department, Cliniques universitaires Saint-Luc, Av. Hippocrate 10, Brussels, 1200, Belgium.
J Ophthalmic Inflamm Infect. 2025 Jul 1;15(1):50. doi: 10.1186/s12348-025-00498-2.
To define a timeframe of recurrences according to the clinical presentation of inflammation and the course of the disease. This could influence final visual acuity and avoid ocular complication such as cataract, glaucoma, choroidal neovascularization, subretinal fibrosis or fundus depigmentation.
Retrospective study of nineteen patients affected by Vogt-Koyanagi-Harada disease followed between 2003 and 2018.
Within our case series, 53% of patients had no recurrence during a follow-up of up to one hundred and sixty-eight months. Among the nine patients with recurrence, five had at least one episode of posterior inflammation, one exhibited both anterior and posterior recurrence, and five developed at least one recurrence in anterior structures. According to the Kaplan Meier method, the overall recurrence-free survival at three months is 68% ± 11%. All posterior segment inflammatory relapses occurred within three months and a half of systemic treatment initiation. On the other hand, the timeline of anterior recurrence is more scattered. They occurred between two and thirty-seven months of treatment initiation. This careful follow-up, which differentiated between types of inflammatory recurrences, made it possible to observe final visual acuity greater than or equal to 9/10 (equivalent ≥ 20/25), with the exception of one amblyopic eye.
The chronological occurrence of posterior inflammatory episodes is earlier than anteriorly. A posterior recurrence does not increase the risk of anterior inflammation relapse during the follow-up. This distinction is important to understand the course of the disease. In fact, the differentiation between the initial acute phase (mainly posterior inflammations) and chronic recurrences (granulomatous anterior segment inflammation) allows for better adaptation of systemic therapy and better visual prognosis in the long term.
根据炎症的临床表现和疾病进程确定复发的时间框架。这可能会影响最终视力,并避免眼部并发症,如白内障、青光眼、脉络膜新生血管、视网膜下纤维化或眼底色素脱失。
对2003年至2018年间随访的19例Vogt-小柳-原田病患者进行回顾性研究。
在我们的病例系列中,53%的患者在长达168个月的随访期间没有复发。在9例复发患者中,5例至少有一次后段炎症发作,1例表现为前段和后段均复发,5例在前段结构中至少有一次复发。根据Kaplan-Meier方法,3个月时的总体无复发生存率为68%±11%。所有后段炎症复发均发生在全身治疗开始后的3个半月内。另一方面,前段复发的时间线更为分散。它们发生在治疗开始后的2至37个月之间。这种仔细的随访区分了炎症复发的类型,使得除一只弱视眼外,能够观察到最终视力大于或等于9/10(相当于≥20/25)。
后段炎症发作的时间早于前段。后段复发在随访期间不会增加前段炎症复发的风险。这种区分对于理解疾病进程很重要。事实上,区分初始急性期(主要是后段炎症)和慢性复发(肉芽肿性前段炎症)有助于更好地调整全身治疗方案,并在长期内获得更好的视力预后。